1. Scrip
  2. >>Business
  3. >>Strategy

Invivyd Moves On From Adintrevimab While Monitoring For New COVID-19 Variants

 
• By Joseph Haas

After changing its name from Adagio, Invivyd explained at IDWeek that its revised strategy is to monitor the virus for emerging variants and develop approaches to prevent or treat them.

Covid variant
Invivyd's new business model centers on monitoring for new COVID-19 variants • Source: Shutterstock

Adjusting to a SARS-CoV-2 virus that is mutating even more quickly than many biopharma companies expected, Adagio Therapeutics, Inc. has undergone a name change to Invivyd Inc., reduced headcount and begun a new strategy focused on addressing emerging variants as its business plan around monoclonal antibody candidate adintrevimab (ADG20) gradually withered.

After renaming from Adagio in September, the Waltham, MA-based company appointed an interim chief financial officer shortly before the IDWeek 2022 conference and cut staff in what new CEO Dave Hering told Scrip should be viewed as “a reallocation of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.